Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07689656 | A Clinical Study of [68Ga]Ga-ELI421 Injection PET Imaging in Patients With Prostate Cancer | recruiting | Phase 1 / Phase 2 | 50 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT01140373 | Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) | active not recruiting | Phase 1 | 13 | Memorial Sloan Kettering Cancer CenterOTHER |
| 1 |
| Jul 7, 2026 |
| clinicaltrials |
| NCT06217822 | First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)(PAnTHA) | recruiting | Phase 1 | 198 | BayerINDUSTRY | 10 | Jul 7, 2026 | clinicaltrials |
| NCT04898634 | A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer | active not recruiting | Phase 1 | 216 | Janssen Research & Development, LLCINDUSTRY | 6 | Jul 6, 2026 | clinicaltrials |
| NCT07682649 | Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer(ESCENDO) | not yet recruiting | Phase 1 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07683013 | Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 | 18 | Hyundai Bioscience Co., Ltd.INDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04887935 | Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer | terminated | Phase 1 | 5 | Washington University School of MedicineOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05938270 | A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.(ASCERTAIN) | completed | Phase 1 | 113 | AstraZenecaINDUSTRY | 6 | Jun 30, 2026 | clinicaltrials |
| NCT03436745 | The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females | terminated | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jun 26, 2026 | clinicaltrials |
| NCT04619069 | Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 60 | Sunnybrook Health Sciences CentreOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05940298 | Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m DB8 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05999968 | Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment | terminated | Phase 1 | 10 | Eli Lilly and CompanyINDUSTRY | 3 | Jun 26, 2026 | clinicaltrials |
| NCT06641219 | Clinical Evaluation of [177Lu]Lu-BQ7876 for Targeting of Prostate-Specific Membrane Antigen | completed | Phase 1 | 7 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT01815749 | Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT02206334 | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer | completed | Phase 1 | 42 | NRG OncologyOTHER | 3 | Jun 25, 2026 | clinicaltrials |
| NCT05079698 | A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer | active not recruiting | Phase 1 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06457919 | A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer | recruiting | Phase 1 / Phase 2 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07668284 | COQ10 and Vitamin E for Off-Target Radiation Toxicity | not yet recruiting | Phase 1 / Phase 2 | 200 | University of NebraskaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04746638 | Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m RM26 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06101927 | Molecular Imaging of Prostate-Specific Membrane Antigen Using Labeled Technetium-99m BQ0413 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04536805 | Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin(REPAIR) | active not recruiting | Phase 1 / Phase 2 | 44 | Institut Cancerologie de l'OuestOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07570966 | Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Jun 22, 2026 | clinicaltrials |
| NCT05708950 | A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | completed | Phase 1 / Phase 2 | 40 | Kineta Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06257264 | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | active not recruiting | Phase 1 | 103 | BeiGeneINDUSTRY | 6 | Jun 18, 2026 | clinicaltrials |
| NCT07407582 | Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS) | recruiting | Phase 1 / Phase 2 | 25 | University of ArizonaOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07503808 | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types | recruiting | Phase 1 | 150 | IDEAYA BiosciencesINDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06318273 | A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 1 | 152 | AbbVieINDUSTRY | 7 | Jun 17, 2026 | clinicaltrials |
| NCT05617885 | Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer | completed | Phase 1 | 9 | Praful Ravi, MB BCHir, MRCPOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07540572 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors | recruiting | Phase 1 | 160 | IDEAYA BiosciencesINDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05398302 | Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy | recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05639972 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | recruiting | Phase 1 / Phase 2 | 15 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07441889 | HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006) | recruiting | Phase 1 / Phase 2 | 23 | University of VirginiaOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04886986 | Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer | recruiting | Phase 1 | 42 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05283330 | Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors | recruiting | Phase 1 | 48 | Orano Med Theranostics, SASINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07641049 | Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer(DUAL-NK-PC) | recruiting | Phase 1 | 36 | Beijing BiotechINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04167969 | The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer | recruiting | Phase 1 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | recruiting | Phase 1 | 40 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07600554 | A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate Cancer(SWAP) | recruiting | Phase 1 | 20 | Philogen S.p.A.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07636707 | QLF4113 in Participants With Metastatic Prostate Cancer | not yet recruiting | Phase 1 | 140 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jun 9, 2026 | clinicaltrials |
| NCT01171898 | Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC) | completed | Phase 1 / Phase 2 | 127 | Aragon Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06609005 | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 84 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 2 | Jun 4, 2026 | clinicaltrials |
| NCT03873805 | PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer | active not recruiting | Phase 1 | 14 | City of Hope Medical CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05375539 | AGN-Cogni.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients | completed | Phase 1 | 12 | Milton S. Hershey Medical CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07198633 | A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer | recruiting | Phase 1 / Phase 2 | 212 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07621692 | Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T | recruiting | Phase 1 | 12 | National Taiwan University HospitalOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04109729 | Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer(Rad2Nivo) | active not recruiting | Phase 1 | 39 | University of UtahOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07145177 | 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer | recruiting | Phase 1 | 30 | University of California, San FranciscoOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07344311 | A Phase I Trial of A-CAR032 in Participants With mCRPC | recruiting | Phase 1 | 27 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02048150 | Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer | completed | Phase 1 | 7 | City of Hope Medical CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 8, 2026source: clinicaltrials